Aurinia Pharmaceuticals Inc. (AUPH) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-10

Key Insights

The reporting person, Greg Keenan, SVP and Chief Medical Officer of Aurinia Pharmaceuticals, disposed of 8,069 shares of common stock to satisfy tax withholding obligations upon the vesting of restricted stock units.
The transaction took place on March 6, 2026, and Keenan continues to beneficially own 154,449 shares of Aurinia's common stock.
The transaction appears to be a routine stock sale for tax purposes and does not suggest any significant changes in Keenan's position or outlook on the company.

Want the newest filings?

This analysis covers the filing from 2026-03-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-02-23

Insider Stephen P. Robertson, EVP and General Counsel, sold 34,638 shares of Aurinia Pharmaceuticals Inc. (AUPH) on February 20, 2026, to cover tax withholding obligations on the vesting of restricted stock units.
After the transaction, Robertson still holds 483,296 shares directly, indicating he maintains a significant equity stake in the company.
The sale appears to be a routine transaction to cover tax liabilities rather than a strategic sale, suggesting no major concerns from this insider.

Filed: 2026-02-23

Joseph M. Miller, the Chief Financial Officer of Aurinia Pharmaceuticals Inc., disposed of 32,424 common shares to satisfy tax withholding obligations on vested restricted stock units.
This transaction represents a relatively small portion (5.5%) of Miller's total beneficial ownership of 556,703 common shares in the company.
Insider transactions, such as this, can provide insights into management's views on the company's prospects, although a single transaction should be interpreted cautiously.

Filed: 2026-02-23

Insider Peter Greenleaf, the Chief Executive Officer, has sold 100,171 shares of Aurinia Pharmaceuticals Inc. (AUPH) on February 20, 2026, likely to cover tax obligations on vested restricted stock units.
Greenleaf still holds a substantial 1,744,866 shares, indicating continued confidence in the company's long-term prospects.
This transaction represents a small portion (around 5%) of Greenleaf's total holdings, suggesting no major shift in his investment position.

Filed: 2026-02-23

The Chief Operating Officer, Matthew Maxwell Donley, disposed of 32,901 shares of Aurinia Pharmaceuticals Inc. (AUPH) on February 20, 2026, likely to satisfy tax withholding obligations upon the vesting of restricted stock units.
Donley's beneficial ownership in AUPH decreased from 695,801 shares to 662,900 shares following this transaction, representing a 4.7% reduction in his stake in the company.
Insider selling transactions, such as this one, can be a signal of management's confidence in the company's near-term outlook and may impact investor sentiment.

Other reports for Aurinia Pharmaceuticals Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.